scispace - formally typeset
N

Neil Pearce

Researcher at University of London

Publications -  795
Citations -  122260

Neil Pearce is an academic researcher from University of London. The author has contributed to research in topics: Population & Asthma. The author has an hindex of 107, co-authored 729 publications receiving 105762 citations. Previous affiliations of Neil Pearce include Harvard University & Victoria University of Wellington.

Papers
More filters
Journal ArticleDOI

Priorities for research on environment, climate and health, a European perspective

TL;DR: The HERA Agenda as mentioned in this paper identifies six thematic research goals in the environment, climate and health fields, including research to reduce the effects of climate change and biodiversity loss on health and environment, promote healthy lives in cities and communities, eliminate harmful chemical exposures, improve health impact assessment and implementation research, develop infrastructures, technologies and human resources and promote research on transformational change towards sustainability.
Posted Content

Analysis proposals for test-negative design and matched case-control studies during widespread testing of symptomatic persons for SARS-Cov-2

TL;DR: The test-negative case-control design (TND) is summarized and explained how to add it to large-scale testing of persons with signs and symptoms, and differences in risk factors between symptomatic persons with COVID-19 and persons with other respiratory infections are shown.
Journal ArticleDOI

Dietary Patterns and Breast Cancer Risk: A Multi-Centre Case Control Study among North Indian Women

TL;DR: Investigating the association between Indian dietary patterns and breast cancer risk in a multi-centre case-control study conducted in the North Indian states of Punjab and Haryana found that lacto-ovo-vegetarians had a lower risk of breast cancer compared to both non-vegarians and lacto/vegetarian peers.
Journal Article

Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine.

TL;DR: 3 x 5 micrograms is the appropriate regimen for protecting children in this age group, as long as cost of vaccine remains a major factor in immunisation programmes.